Literature DB >> 2484881

Enhanced immunogenicity of a T cell immunogenic peptide by modifications of its N and C termini.

P M Allen1, G R Matsueda, S Adams, J Freeman, R W Roof, L Lambert, E R Unanue.   

Abstract

The modification of the terminal ionizable charges of an immunogenic peptide, HEL (46-61), was found to greatly increase the immunogenicity of the peptide. The modified peptide had 100- to 1000-fold enhanced activity in both in vitro and in vivo T cell assays. The mechanism of the enhancement was investigated by determining the binding affinities to I-Ak as well as circular dichroism (CD) studies. The native and enhanced peptides had indistinguishable binding affinities, as well as similar kinetics. The CD studies revealed that in aqueous solution, neither peptide had any detectable helicity; however, the addition of trifluoroethanol did result in significant helicity; with the two peptides being indistinguishable. These same modifications were also shown to enhance other immunogenic peptides if they contained a basic carboxy-terminal amino acid residue. Thus, by modifying the termini of T cell epitopes, their immunogenicity can be dramatically increased, but the molecular basis for this enhancement is still unclear.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2484881     DOI: 10.1093/intimm/1.2.141

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  10 in total

Review 1.  Cellular mechanisms of antigen processing and the function of class I and II major histocompatibility complex molecules.

Authors:  C V Harding; E R Unanue
Journal:  Cell Regul       Date:  1990-06

2.  Short-lived complexes between myelin basic protein peptides and IAk.

Authors:  K Mason; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

3.  Identification of two distinct properties of class II major histocompatibility complex-associated peptides.

Authors:  C A Nelson; S J Petzold; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

4.  Interferon-gamma differentially regulates antigen-processing functions in distinct endocytic compartments of macrophages with constitutive expression of class II major histocompatibility complex molecules.

Authors:  R D Hockett; J R Cook; K Findlay; C V Harding
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

5.  Different strategies adopted by K(b) and L(d) to generate T cell specificity directed against their respective bound peptides.

Authors:  Natalie A Bowerman; Leremy A Colf; K Christopher Garcia; David M Kranz
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

6.  Regulation of the immune response to peptide antigens: differential induction of immediate-type hypersensitivity and T cell proliferation due to changes in either peptide structure or major histocompatibility complex haplotype.

Authors:  P Soloway; S Fish; H Passmore; M Gefter; R Coffee; T Manser
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

7.  Phospholipids enhance the binding of peptides to class II major histocompatibility molecules.

Authors:  R W Roof; I F Luescher; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  Unconventional T-cell recognition of an arthritogenic epitope of proteoglycan aggrecan released from degrading cartilage.

Authors:  Jane Falconer; Rahul Mahida; Divya Venkatesh; Jeffrey Pearson; John H Robinson
Journal:  Immunology       Date:  2015-12-21       Impact factor: 7.397

9.  Delineation of antigen contact residues on an MHC class II molecule.

Authors:  J Peccoud; P Dellabona; P Allen; C Benoist; D Mathis
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

Review 10.  Conserved Binding Regions Provide the Clue for Peptide-Based Vaccine Development: A Chemical Perspective.

Authors:  Hernando Curtidor; César Reyes; Adriana Bermúdez; Magnolia Vanegas; Yahson Varela; Manuel E Patarroyo
Journal:  Molecules       Date:  2017-12-12       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.